Dr. Deepa Gali, MD
Rheumatology (Rheumatology Physician)
11311 Bridgeport Way Sw Ste 100
Lakewood, WA 98499
Who else practices at this address →
Pierce County includes primary care (20% of residents) and dental (11% of residents) and mental health (11% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 230
Licensed in Washington since 2015, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
WA license MD60616582 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Overlake Hospital Medical Center & Clinics Bellevue, WA
- Evergreenhealth Medical Center Kirkland, WA
Medical groups
- Overlake Arthritis and Osteoporosis Center PLLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 230
- Services billed
- 26,603
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 660 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 219 | 153 |
| New patient office or other outpatient visit, 60-74 minutes | 58 | 58 |
| Established patient office or other outpatient visit, 40-54 minutes | 49 | 45 |
| Dxa bone density measurement of hip, pelvis, spine | 19 | 19 |
| New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
| Injection of drug or substance under skin or into muscle | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 90 payments worth $2,198 in total to this clinician.
| Janssen Biotech, Inc. | $544 |
|---|---|
| AbbVie Inc. | $367 |
| Amgen Inc. | $364 |
| UCB, Inc. | $155 |
| Novartis Pharmaceuticals Corporation | $109 |
| Lilly USA, LLC | $83.86 |
| Radius Health, Inc. | $82.38 |
| Fidia Pharma USA Inc. | $74.95 |
| Food and Beverage | $2,121 |
|---|---|
| Education | $76.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Nov 6, 2025 | Education TREMFYA · Immunology · in-kind | $76.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $160,425 in research payments for these studies, mostly to the institutions running them.
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT05848258
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.